ABCB1

ATP-dependent translocase ABCB1 · P08183 · ABCB1 on Sugi Atlas →

353,607 patent compounds predicted against ABCB1, 226,390 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Propafenone (SCHEMBL27865)	1.00	17/20
Propafenone (SCHEMBL41413)	1.00	17/20
Propafenone (SCHEMBL41412)	0.98	17/20
Valspodar (SCHEMBL17879)	1.00	14/20
Cyclosporine (SCHEMBL3490)	1.00	13/20
Cyclosporine (SCHEMBL3491)	1.00	13/20
Cyclosporine (SCHEMBL4442)	1.00	13/20
Cyclosporine (SCHEMBL4443)	1.00	13/20
Cyclosporine (SCHEMBL17555)	1.00	13/20
Geclosporin (SCHEMBL7791)	0.91	13/20
Beauvericin (SCHEMBL29355)	0.55	12/20
Cyclosporine (SCHEMBL3489)	0.67	11/20
Verapamil (SCHEMBL16742)	1.00	9/20
Dexverapamil (SCHEMBL33297)	1.00	9/20
Verapamil (SCHEMBL33296)	0.98	9/20
Verapamil (SCHEMBL33305)	0.96	9/20
(-)-Cromakalim (SCHEMBL12833)	0.55	8/20
Cytochalasin D (SCHEMBL33528)	0.33	8/20
Cytochalasin D (SCHEMBL33529)	0.33	8/20
Kaempferol (SCHEMBL18817)	1.00	7/20

Clinical trials — most relevant to ABCB1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Pharmacogenetics to Predict Drug Interactions in Kidney Transplant Recipients	PHASE4	COMPLETED
Influence of the MDR1 Genotype on Blood Levels of Indinavir and Saquinavir in Healthy Volunteers	PHASE4	COMPLETED
Therapy for Children With Neuroblastoma	PHASE2	COMPLETED
The Effect of Perioperative Ketamine on Acute and Chronic Pain After Major Back Surgery	PHASE2	COMPLETED
A Phase 2 Trial of SCO-101 in Combination With FOLFIRI for Patients With Metastatic Colorectal Cancer (mCRC) With Acquired Resistance to FOLFIRI	PHASE1/PHASE2	UNKNOWN
FGFR4 Inhibitor EVER4010001 in Combination With PD-1 Inhibitor Pembrolizumab in Patients With Advanced Solid Tumors	PHASE1/PHASE2	UNKNOWN
Influence of Ethnicity and ABCB1 Gene Polymorphism on the Pharmacokinetics of Azithromycin in Healthy Bangladeshi Volunteers	PHASE1	UNKNOWN
mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Previously Treated Glioblastoma Multiforme	PHASE1	COMPLETED
Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery	PHASE1	COMPLETED
Study to Access Anti-CD38 Anibody Drug in Patients With Advanced Solid Tumors	PHASE1	UNKNOWN
AZD2014 Plus Novel Anti-Cancer Agents in Relapsed or Refractory Diffuse Large B-Cell Lymphoma	PHASE1	WITHDRAWN
Icotinib Hydrochloride in Treating Patients With Advanced Cancers	PHASE1	WITHDRAWN
Drug Cocktail Interaction Study of St. John's Wort Dry Extract Ze 117	PHASE1	COMPLETED
Evaluation of Pharmacogenetic Factors Affecting Fentanyl Requirements for Postoperative Pain Control	nan	COMPLETED
Transplacental Transfer of Drugs Used in Pregnant Women	nan	COMPLETED
the Effect of ABCC2 Genetic Polymorphism on Neurotoxicity in Gastrointestinal Cancer Patients Receiving Oxaliplatin	nan	UNKNOWN
Pharmacogenomics of New Antiretrovirals	nan	COMPLETED
Multidrug Resistance Genes in Patients With Acute Myeloid Leukemia	nan	ACTIVE_NOT_RECRUITING
TyrosIne Kinase Inhibitors in Chronic Myeloid Leukemia: Efficacy and Tolerability. The TIKlet Study	nan	COMPLETED
Impact of Genetics on Metformin Pharmacokinetics	nan	COMPLETED
Pharmacogenetics Study in Taiwan's Ethnic Groups	nan	COMPLETED
A Prospective Study on Effect of Systemic Adjuvant Therapy on Cognitive and Brain Function of Breast Cancer Patients	nan	UNKNOWN
A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment	nan	RECRUITING
Study of CYP2C19 and ALDH3A1 Polymorphisms in Breast Cancer Patients	nan	UNKNOWN
Clinical Features and Potential Etiology of Epilepsy and Nodding Syndrome in the Mahenge Area, Ulanga District	nan	UNKNOWN
Placental Transfer of Tenofovir	nan	COMPLETED
Role of Gene Variation in Effectiveness of Gleevec Treatment	nan	COMPLETED
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Refractory Solid Tumors	nan	WITHDRAWN
Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant	nan	RECRUITING
Effectiveness of Raltegravir-Based Antiretroviral Therapy in HIV-HCV Coinfected Liver Transplant Recipients	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a ABCB1 binder may also engage these)

Protein	Name	Similarity
P21449	—	1.000	P21449 →
P06795	—	1.000	P06795 →
P23174	—	1.000	P23174 →
P21440	—	1.000	P21440 →
P21448	—	1.000	P21448 →
P21447	—	1.000	P21447 →
Q08201	—	1.000	Q08201 →
ABCB4	Phosphatidylcholine translocator ABCB4	0.998	landscape →
O80725	—	0.998	O80725 →
P43245	—	0.997	P43245 →
Q9QY30	—	0.997	Q9QY30 →
B8K1W2	—	0.995	B8K1W2 →
Q9M1Q9	—	0.992	Q9M1Q9 →
Q9M0M2	—	0.992	Q9M0M2 →
Q9FHF1	—	0.992	Q9FHF1 →
Q9N0V3	—	0.991	Q9N0V3 →
Q9SYI3	—	0.990	Q9SYI3 →
Q9LJX0	—	0.990	Q9LJX0 →
ABCB11	Bile salt export pump	0.989	landscape →
B5X0E4	—	0.989	B5X0E4 →
Q9FWX7	—	0.988	Q9FWX7 →
O70127	—	0.988	O70127 →
Q2M3G0	—	0.988	Q2M3G0 →
Q9ZR72	—	0.988	Q9ZR72 →
Q9SYI2	—	0.987	Q9SYI2 →
Q9FWX8	—	0.986	Q9FWX8 →
F1M3J4	—	0.985	F1M3J4 →
Q54BT3	—	0.985	Q54BT3 →
Q7FB56	—	0.984	Q7FB56 →
P34712	—	0.983	P34712 →